sitefansalaran Industry News

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial. Semaglutide is the active ingredient in Novo Nordisk's (NOVOb.CO), opens new tab diabetes drugs Ozempic and Rybelsus, as well as its weight-loss treatment Wegovy. In the first clinical trial testing the Novo drug in people with type 1 diabetes and obesity, the 36 patients who received weekly semaglutide injections along with their usual insulin spent more time in their target blood sugar range and lost more weight than 36 similar patients who got a placebo along with their insulin, study leader Dr. Viral Shah of Indiana University School of Medicine reported at the American Diabetes Association meeting in Chicago. All of the patients were using automated insulin delivery systems and had a body mass index of 30 or higher, which is considered obese. One-third of the patients in the semaglutide group achieved all three of the study’s goals: blood sugar in the target range of 70 to 180 mg/dL more than 70% of the time, dangerously low blood sugar less than 4% of the time, and body weight reduction of at...

-U.S. Trade Representative Jamieson Greer made clear in a meeting with Irish Trade Minster Simon Harris last month that Washington was open to "creative solutions" on pharmaceutical trade between the U.S. and European Union, Harris said on Wednesday. "He made it clear that he was open to creative solutions when it comes to pharma and I think that's an important recognition that actually pharma between the U.S. and the EU, the U.S. and Ireland, is much more interdependent than perhaps people were led to believe in certain quarters at the start of this process," Harris told reporters. The European Union wants immediate relief from tariffs in key sectors as part of any trade deal with the U.S. due by a July 9 deadline, EU diplomats have told Reuters, even as they accept the U.S. baseline tariff of 10% as unavoidable. The EU also wants a deal to cover commercial aircraft and parts, pharmaceuticals and semiconductors, sectors the U.S. is investigating, but has not yet imposed extra duties on. Trump said in June the pharma duties would be announced "very soon". "I think it's important to be truthful with people, the EU is negotiating with an administration that believes in tariffs and clearly I...

The Europe Pharmaceutical Drugs industry in Europe is witnessing transformative growth driven by advancements in drug development, precision medicine, and increasing demand for biologics and specialty medications. Regulatory frameworks and policy shifts continue to shape market dynamics, influencing innovation cycles and market opportunities. The Europe Pharmaceutical Drugs Market size is estimated to be valued at USD 450 billion in 2025 and is expected to reach USD 610 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.5% from 2025 to 2032. This robust growth forecasts substantial business growth and evolving market trends aligned with scientific progress and demographic shifts. The increasing prevalence of chronic diseases coupled with investment in R&D underscores the sustained market revenue growth and competitive environment.

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous type of brain swelling, the company said on Wednesday. Kisunla, given as a monthly infusion, is part of a class of drugs designed to clear an Alzheimer's-related protein called beta amyloid from the brain. It was approved by the FDA just over a year ago for adults with early-stage Alzheimer's after a study showed it slowed progression of memory and thinking problems by 29% compared with a placebo. The FDA placed its strongest "boxed" safety warning on Kisunla's prescribing label, flagging the risk of potentially life-threatening brain swelling and bleeding. Lilly presented study data last year showing that after 24 weeks of treatment, 24% of patients given the standard Kisunla regimen experienced a side effect called ARIA-E, a kind of brain swelling, compared with 14% of those on more gradual dosing. The altered schedule did not compromise Kisunla's ability to reduce amyloid brain plaques, the company said. The new dosing recommendation is to start with a single vial, adding a vial each month until reaching the full four-vial dose at month four. The previous...

Gilead Sciences (GILD.O), opens new tab and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the absence of funding from a key U.S. initiative aimed at addressing the global HIV/AIDS epidemic. Under the agreement, Gilead said it will supply, at cost, enough doses to reach up to 2 million people over three years in countries supported by the Global Fund. Both parties said price terms are confidential, and the Global Fund declined to comment further on how many doses would be ordered immediately. The U.S. Food and Drug Administration last month approved Gilead's lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents. The World Health Organization and other regulators are currently reviewing it. Last year, Gilead signed royalty-free deals allowing six generic drugmakers to make and sell low-cost versions of the drug in 120 low- and middle-income countries, but those supplies will take time to get up and running. Some AIDS experts have said the new drug could help end the 44-year-old epidemic that infects 1.3 million people a year and is estimated by the World Health Organization to have killed...

Merck (MRK.N), opens new tab is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda. The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare diseases and obesity. Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data compiled by LSEG, up 7% from year-ago levels and the highest year-to-date total since 2023.

Some poorer nations hit by cuts in HIV/AIDS funding from rich donors have boosted their own spending in response, but not enough to make up for huge staff losses and drops in preventative drug use, UNAIDS said on Thursday. In its annual report for 2025, launched in South Africa, the agency also reiterated that if the Trump administration's cuts to the U.S. HIV programme remain permanent, there could be 6 million extra infections and 4 million more deaths by 2029. Trump's sudden slashing of finance for the President's Emergency Plan for AIDS Relief (PEPFAR) threw the global response to HIV/AIDS into disarray. Although many countries still have enough life-saving antiretroviral drugs, clinics aimed at vulnerable groups such as gay men, sex workers and teenage girls have shut due to a lack of paid staff, and prevention programmes have all but petered out. "Prevention was hit harder than treatment. Key populations were the worst affected ... they depended on tailored services by community leaders, and those were the first to go," UNAIDS Executive Director Winnie Byanyima told Reuters in an interview in Johannesburg. Byanyima said that even before the Trump cuts, donors were scaling back development assistance, notably European countries. "They've told us that it has...

Severe Allergic Reactions to Indian Medications Make Headlines Emergency Import of Fibrinogen Amin Afshar, Chairman of the Board of the Iranian Hemophilia Society, stated: Due to the failure to return plasma-derived products to the country, the Food and Drug Administration has come under pressure and was forced to request emergency imports of fibrinogen from India. As a result of using this imported fibrinogen from Indian warehouses, many patients have experienced respiratory disorders and severe allergic reactions. On the other hand, due to poor health oversight in pharmaceutical production in India, continuing this approach may lead to the spread of bloodborne viruses, as occurred during the 1970s and 1980s. Unfortunately, the system is dysfunctional, and certain individuals are exploiting this lack of governance and disorder. Oversight of this process falls under the Food and Drug Administration, but this organization neither monitors the plasma import process nor ensures its return to the country, and it fails to refer the involved companies to the judiciary for accountability.

در اینجا ترجمه دقیق و رسمی متن شما به انگلیسی: Policy-Making Without Regulation A Report on Changes in Medicine Prices We review a recent report by Siavash Eftekhari, in which he states: "In recent years, changes in the prices of pharmaceutical products have not followed any clear or regulated pattern. Policymakers have often adopted non-transparent and sometimes arbitrary approaches." In analyzing the price increases, a comparison of drug price trends with macroeconomic indicators, such as general inflation and currency exchange rates, shows that the rise in medicine prices has not aligned with the country’s overall economic conditions, and in some cases, has been significantly lower than expected, especially when compared to other essential goods like food. Establishing a transparent framework based on sound economic principles for drug price policy is essential. The instability in current policies has not only enabled some producers to raise prices disproportionately, but has also put more critical sectors of the pharmaceutical industry at risk.

در اینجا ترجمه دقیق و رسمی متن شما به انگلیسی: Pharmacies for Special Patients Active During Nowruz Holidays The Minister of Health stated: “We have no shortage of medicine. On-call pharmacies will operate according to schedule during the Nowruz holidays, and 24-hour pharmacies will remain fully available. Therefore, there will be no issues in providing the medications needed by the public.” He also emphasized that pharmacies supplying medications for special patients will continue their activities throughout the Nowruz period.